Abstract
This study was conducted to evaluate the serum soluble endoglin (CD105) levels in preeclamptic and normotensive pregnant women after 22 weeks of pregnancy. One hundred pregnant women from 22 weeks of gestation till term were divided into 2 groups in this case control study. Group I included 50 women with features of preeclampsia while Group II had 50 gestationally matched normotensive controls. Soluble endoglin levels were measured by Enzyme-linked immunosorbent assay (ELISA) and results analysed. The endoglin levels in the study varied between 2.37 to 77.77 mg/ml. The levels were significantly higher in Group I and were inversely proportional to the gestational age. The maternal and neonatal outcomes were better in Group II of the study. Serum soluble endoglin could be of possible use as a predictive clinical test for preeclampsia risk assessment. Key words: Soluble endoglin, preeclampsia.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
